Skip to main content
Bristol Myers Squibb8-K: Product launch

FDA Approves Camzyos for Obstructive Hypertrophic Cardiomyopathy and Zenbexus Brings First-in-Class Multiple Myeloma Treatment

Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Bristol Myers Squibb received FDA approval on September 30, 2026, for Camzyos to treat pediatric and adult obstructive hypertrophic cardiomyopathy, alongside regulatory approval of Zenbexus for multiple myeloma.

Source

SEC EDGAROct 29, 2026

Current report (Form 8-K)

Bristol Myers Squibb 8-K

Filing excerpt

The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones.

sec.gov/Archives/edgar/data/14272/000001427226000022/bmy-20261029.htmRead the full source

Other signals in this filing (2)

Extracted by Autobound

From the Signal API record
Signal
8-K: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
10/29
Filed
Oct 29, 2026

The full record

From the Signal API record

Details

CIK
14272
Accession number
0000014272-26-000022
Timeframe
Current quarter
Filing year
2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 3, 2026
signal_type
sec-8k
signal_subtype
productLaunch

Use this data

Get every 8-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e256edc1-0efc-4561-ab07-90b6800757f1 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "e256edc1-0efc-4561-ab07-90b6800757f1",
  "signal_type": "sec-8k",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-03T07:05:06.403+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "detail": "Bristol Myers Squibb received FDA approval on September 30, 2026, for Camzyos to treat pediatric and adult obstructive hypertrophic cardiomyopathy, alongside regulatory approval of Zenbexus for multiple myeloma. This rollout may create opportunities for commercialization vendors, specialized distribution partners, and digital healthcare engagement platforms.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "FDA Approves Camzyos for Obstructive Hypertrophic Cardiomyopathy and Zenbexus Brings First-in-Class Multiple Myeloma Treatment",
    "excerpts": "The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/bmy-20261029.htm",
    "filing_date": "2026-10-29",
    "filing_year": 2026,
    "fiscal_year_end": "10/29",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.